Table 2 Outcomes for 24 patients with metastatic MITF family translocation renal cell carcinoma treated with an immune checkpoint inhibitor (ICI)
Patient number | Sex | Age at diagnosis, years | Translocation type | TNM at diagnosis | FISH analysis | Karnofsky score | Heng score (IDMC criteria) | First treatment line | Response to 1st line | PFS (mo) | Immunotherapy treatment | ICI line | Response to ICI | Duration of response (mo) | Deseased | Survival (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 25 | TFE B | T3N2M1 | available | 100 | 2 | Sunitinib | PD | 2 | Ipilimumab | 4 | PR | 9.0 | no | 40 |
2 | F | 3 | TFE 3+ | TxN0M0 | available | 100 | 1 | Sunitinib | PD | 1 | Ipilimumab | 5 | PD | 2.5 | yes | 23.5 |
3 | F | 13.7 | TFE 3+ | T2N + M+ | available | 60 | 3 | Pazopanib | PR | 4 | Ipilimumab | 3 | PD | 2,0 | yes | 20.7 |
4 | F | 10 | TFE 3+ | TxNxM0 | available | < 80 | 1 | Everolimus | PD | 4.4 | Atezolizumab | 2 | PD | 0.8 | no | 19 |
5 | F | 35.5 | TFE 3+ | T2bN1Mx | available | 100 | 4 | Sunitinib | PD | 4.4 | Nivolumab | 5 | PD | 1.0 | yes | 24.5 |
6 | M | 22 | TFE 3+ | pT1bNxM0 | available | 100 | 1 | Sunitinib | PD | 1 | Nivolumab | 2 | PR | 8.3 | no | 17 |
7 | F | 26.7 | TFE 3+ | pT1bNxMxR1 | available | 100 | 0 | Sunitinib | PD | 4 | Nivolumab | 3 | PD | 2.4 | no | 25 |
8 | M | 60.7 | TFE B | pT3cN0M1R1 | available | 100 | 1 | Sunitinib | PD | 3.1 | Nivolumab | 3 | PD | 2.5 | yes | 19.5 |
9 | F | 35 | TFE 3+ | pT3aN1Mx | available | 100 | 1 | Sunitinib | PD | 2.7 | Nivolumab | 2 | PD | 1.0 | yes | 9.6 |
10 | M | 41.9 | TFE 3+ | pT3bN1Mx | no | 90 | 1 | Pazopanib | PD | 1.2 | Nivolumab | 2 | PD | 1.4 | yes | 8.5 |
11 | F | 35.1 | TFE 3+ | T3cN0M0 | available | 90 | 1 | High dose IL-2 | PD | 0.1 | MEDI4736 + Tremelimumab | 4 | PD | 2.4 | yes | 16.9 |
12 | F | 16.1 | TFE 3+ | T1aN1M1 | available | 70 | 2 | Sunitinib +nivolumab | SD | 3.2 | Sunitinib +nivolumab | 1 | PR | 3.2 | yes | 7.6 |
13 | F | 79.5 | TFE 3+ | T3aN0M0 | available | 60 | 1 | Temsirolimus | SD | 1.2 | Nivolumab | 5 | PD | 1.0 | yes | 17.3 |
14 | F | 54 | TFE 3+ | T2aN0M1 | available | 80 | 2 | Pazopanib | PR | 17.2 | Nivolumab | 2 | SD | 15.4 | no | 84.6 |
15 | F | 42.8 | TFE 3+ | T3N + M+ | available | 100 | 1 | Sunitinib | SD | 22 | Nivolumab | 4 | PD | 9.0 | no | 59 |
16 | M | 32 | TFE B | T3bN0M1 | available | 80 | 0 | Sunitinib | PD | 1 | Nivolumab | 2 | SD | 14 | no | 25 |
17 | F | 29.4 | TFE 3+ | T4N1M1 | available | 80 | 5 | Pazopanib | SD | 3 | Nivolumab | 2 | PD | 3 | no | 4 |
18 | F | 26.7 | TFE 3+ | NA | no | 90 | 2 | Sunitinib | SD | 15 | pembro +41BB agonist | 3 | PR | 30 | yes | 60 |
19 | F | 49 | TFE 3+ | pT4pN1pM1 | no | NA | 1 | Sunitinib | PD | 3 | Nivolumab | 2 | SD | 8.5 | yes | 19 |
20 | F | 43 | TFE 3+ | T3bN0M0 | available | 90 | 1 | Sunitinib | PD | 1.5 | Nivolumab | 3 | PD | 1 | yes | 8 |
21 | F | 63 | TFE 3+ | pT3aNxMx | available | 90 | 1 | Sunitinib | PD | 6 | Nivolumab | 5 | PD | 2 | yes | 24 |
22 | F | 48.2 | TFE 3+ | T3NxM1 | available | 70 | 3 | Sunitinib | PD | 3 | Nivolumab | 2 | PD | 2 | no | 5 |
23 | F | 45 | TFE 3+ | pT3aNxM1R1 | available | 80 | 1 | Sunitinib | PD | 2 | Nivolumab | 2 | PD | 3 | yes | 9 |
24 | F | 24 | TFE 3+ | pT2bN1 | available | NA | 1 | Sorafenib | SD | 12 | Nivolumab | 3 | PD | 4 | no | 70 |